| Protocol No. | RTOG-0924 | Principal Investigator | Roach III, Mack |
| Phase | III (Cancer Control) |
| Age Group | Adult | Scope | National |
| Secondary Protocol No. | 0924 |
| Title | Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
|
| Objective | Demonstrate that prophylactic neoadjuvant androgen deprivation therapy (NADT) and whole- pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) in patients with ““unfavorable”” intermediate risk or ““favorable”” high risk prostate cancer compared to NADT and high dose prostate and seminal vesicle (SV) radiation therapy (P + SV RT) using intensity modulated radiotherapy (IMRT) or EBRT with a high dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost |
|
|
| Key Eligibility | * Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence
* Clinically negative lymph nodes as established by imaging
* No evidence of bone metastases (M0) on bone scan |
| Applicable Disease Sites | Prostate |
|
| Therapies Involved | Radiotherapy |
|
| Status | Open |
| Participating Institutions | Mt. Zion : Frances Zhang
Parnassus : Frances Zhang
University of California San Francisco : Frances Zhang |
|
| Eligibility Document | RTOG-0924_CTGov_Eligibility_NCT01368588.doc |
|
| Contact | Frances Zhang |
Phone:415-353-9857
Pager:
Email:fzhang@radonc.ucsf.edu |